National Research Past Earnings Performance
Past criteria checks 2/6
National Research's earnings have been declining at an average annual rate of -0.6%, while the Healthcare industry saw earnings growing at 5.6% annually. Revenues have been growing at an average rate of 5% per year. National Research's return on equity is 63.3%, and it has net margins of 20.8%.
Key information
-0.6%
Earnings growth rate
0.6%
EPS growth rate
Healthcare Industry Growth | 8.5% |
Revenue growth rate | 5.0% |
Return on equity | 63.3% |
Net Margin | 20.8% |
Next Earnings Update | 07 May 2024 |
Recent past performance updates
Recent updates
National Research's (NASDAQ:NRC) Dividend Will Be $0.12
Feb 20National Research (NASDAQ:NRC) Will Pay A Dividend Of $0.12
Dec 13Many Would Be Envious Of National Research's (NASDAQ:NRC) Excellent Returns On Capital
Oct 01We Think National Research (NASDAQ:NRC) Can Stay On Top Of Its Debt
Jul 10Why We Like The Returns At National Research (NASDAQ:NRC)
May 04Does National Research (NASDAQ:NRC) Have A Healthy Balance Sheet?
Mar 25National Research (NASDAQ:NRC) Will Pay A Dividend Of $0.12
Nov 17National Research Corp: Market Is Discounting These Key Factors
Sep 18National Research declares $0.24 dividend
Aug 23National Research GAAP EPS of $0.33, revenue of $37.3M
Aug 02National Research (NASDAQ:NRC) Knows How To Allocate Capital Effectively
Jul 13Does National Research (NASDAQ:NRC) Have A Healthy Balance Sheet?
May 27National Research Corp.: Quality/Low Risk On Sale
May 17The Trend Of High Returns At National Research (NASDAQ:NRC) Has Us Very Interested
Mar 21National Research (NASDAQ:NRC) Seems To Use Debt Rather Sparingly
Feb 11National Research (NASDAQ:NRC) Is Achieving High Returns On Its Capital
Nov 25Is National Research (NASDAQ:NRC) A Risky Investment?
Nov 02National Research (NASDAQ:NRC) Seems To Use Debt Rather Sparingly
Jul 15Revenue & Expenses BreakdownBeta
How National Research makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 149 | 31 | 47 | 0 |
30 Sep 23 | 149 | 29 | 46 | 0 |
30 Jun 23 | 148 | 29 | 45 | 0 |
31 Mar 23 | 150 | 30 | 44 | 0 |
31 Dec 22 | 152 | 32 | 43 | 0 |
30 Sep 22 | 152 | 35 | 42 | 0 |
30 Jun 22 | 152 | 36 | 41 | 0 |
31 Mar 22 | 151 | 37 | 40 | 0 |
31 Dec 21 | 148 | 37 | 39 | 0 |
30 Sep 21 | 144 | 36 | 38 | 0 |
30 Jun 21 | 140 | 36 | 36 | 0 |
31 Mar 21 | 135 | 35 | 35 | 0 |
31 Dec 20 | 133 | 37 | 34 | 0 |
30 Sep 20 | 131 | 38 | 34 | 0 |
30 Jun 20 | 130 | 36 | 35 | 0 |
31 Mar 20 | 130 | 36 | 34 | 0 |
31 Dec 19 | 128 | 32 | 33 | 0 |
30 Sep 19 | 126 | 31 | 33 | 0 |
30 Jun 19 | 124 | 30 | 32 | 0 |
31 Mar 19 | 120 | 31 | 31 | 0 |
31 Dec 18 | 120 | 30 | 31 | 0 |
30 Sep 18 | 119 | 29 | 31 | 0 |
30 Jun 18 | 118 | 26 | 32 | 0 |
31 Mar 18 | 118 | 24 | 31 | 0 |
31 Dec 17 | 118 | 23 | 30 | 0 |
30 Sep 17 | 116 | 22 | 29 | 0 |
30 Jun 17 | 114 | 23 | 27 | 0 |
31 Mar 17 | 112 | 21 | 28 | 0 |
31 Dec 16 | 109 | 20 | 28 | 0 |
30 Sep 16 | 107 | 21 | 28 | 0 |
30 Jun 16 | 106 | 20 | 28 | 0 |
31 Mar 16 | 104 | 19 | 27 | 0 |
31 Dec 15 | 102 | 17 | 27 | 0 |
30 Sep 15 | 101 | 16 | 28 | 0 |
30 Jun 15 | 100 | 16 | 27 | 0 |
31 Mar 15 | 99 | 16 | 26 | 0 |
31 Dec 14 | 99 | 18 | 25 | 0 |
30 Sep 14 | 97 | 18 | 24 | 0 |
30 Jun 14 | 95 | 17 | 25 | 0 |
31 Mar 14 | 94 | 16 | 25 | 0 |
31 Dec 13 | 93 | 15 | 25 | 0 |
30 Sep 13 | 92 | 15 | 25 | 0 |
30 Jun 13 | 91 | 15 | 25 | 0 |
Quality Earnings: NRC has high quality earnings.
Growing Profit Margin: NRC's current net profit margins (20.8%) are lower than last year (21%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NRC's earnings have declined by 0.6% per year over the past 5 years.
Accelerating Growth: NRC's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: NRC had negative earnings growth (-2.6%) over the past year, making it difficult to compare to the Healthcare industry average (12.5%).
Return on Equity
High ROE: NRC's Return on Equity (63.3%) is considered outstanding.